BR112021019003A2 - Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer - Google Patents

Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer

Info

Publication number
BR112021019003A2
BR112021019003A2 BR112021019003A BR112021019003A BR112021019003A2 BR 112021019003 A2 BR112021019003 A2 BR 112021019003A2 BR 112021019003 A BR112021019003 A BR 112021019003A BR 112021019003 A BR112021019003 A BR 112021019003A BR 112021019003 A2 BR112021019003 A2 BR 112021019003A2
Authority
BR
Brazil
Prior art keywords
nanoparticles
poly
alkyl cyanoacrylate
cancer treatment
cyanoacrylate
Prior art date
Application number
BR112021019003A
Other languages
English (en)
Inventor
Einar Sulheim
Heidi Johnsen
Giller Fleten Karianne
Kjersti Flatmark
Per Stenstad
Ruth Schmid
Yrr Mørch
Original Assignee
Univ Oslo Hf
Sintef Tto As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf, Sintef Tto As filed Critical Univ Oslo Hf
Publication of BR112021019003A2 publication Critical patent/BR112021019003A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer. é aqui descrito uma droga anticâncer hidrofóbica encapsulada em nanopartículas de poli (alquil cianoacrilato) e seu uso em tratamentos de câncer por rota de administração intracavitária, tal como administração intraperitoneal.
BR112021019003A 2018-03-27 2019-09-26 Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer BR112021019003A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180429 2018-03-27
US16/366,596 US11806330B2 (en) 2018-03-27 2019-03-27 PACA and cabazitaxel for anti-cancer treatment
PCT/EP2019/076121 WO2020192950A1 (en) 2018-03-27 2019-09-26 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer

Publications (1)

Publication Number Publication Date
BR112021019003A2 true BR112021019003A2 (pt) 2021-11-30

Family

ID=66049182

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112020019452-2A BR112020019452A2 (pt) 2018-03-27 2019-03-27 Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer
BR112021019003A BR112021019003A2 (pt) 2018-03-27 2019-09-26 Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112020019452-2A BR112020019452A2 (pt) 2018-03-27 2019-03-27 Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer

Country Status (8)

Country Link
US (3) US20210113482A1 (pt)
EP (2) EP3773471A1 (pt)
JP (2) JP7317038B2 (pt)
CN (2) CN111989087A (pt)
AU (1) AU2019437385A1 (pt)
BR (2) BR112020019452A2 (pt)
CA (1) CA3134923A1 (pt)
WO (2) WO2019185685A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020019452A2 (pt) * 2018-03-27 2021-01-05 Sintef Tto As Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer
US11957793B2 (en) * 2018-08-23 2024-04-16 Sintef Tto As Nanoparticles
IL295800A (en) * 2020-02-26 2022-10-01 Biosergen As Therapeutic polyene macrolide pharmaceutical preparations and methods of using them

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872703B1 (fr) * 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
US20090117177A1 (en) 2005-05-23 2009-05-07 Natalia Rapoport Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
EP1876188A1 (en) 2006-07-04 2008-01-09 NanoDel Technologies GmbH Two step miniemulsion process
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
FR2921660B1 (fr) 2007-10-01 2015-09-25 Centre Nat Rech Scient Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer.
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
EP2508207B1 (en) * 2011-03-31 2013-05-08 BioAlliance Pharma Nanoparticles loaded with chemotherapeutic antitumoral Drug
WO2014065513A1 (ko) 2012-10-25 2014-05-01 서강대학교 산학협력단 약물을 함유한 나노입자가 결합된 초음파 조영제 및 이의 제조방법
US10967039B2 (en) * 2013-05-28 2021-04-06 Sintef Tto As Process for preparing stealth nanoparticles
US10391185B2 (en) 2014-11-26 2019-08-27 Fujifilm Visualsonics, Inc. Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles
WO2016134115A1 (en) 2015-02-20 2016-08-25 Trustees Of Boston University Theranostic compositions and uses thereof
US10925852B2 (en) * 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
WO2017078099A1 (ja) * 2015-11-06 2017-05-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
ES2861449T3 (es) * 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
WO2017143967A1 (zh) 2016-02-24 2017-08-31 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途
KR20170133257A (ko) 2016-05-24 2017-12-05 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
NO342271B1 (en) * 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer
WO2018060437A1 (en) * 2016-09-29 2018-04-05 Sintef Tto A new drug delivery system for treatment of disease
BR112020019452A2 (pt) 2018-03-27 2021-01-05 Sintef Tto As Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer
US20220257525A1 (en) 2019-03-27 2022-08-18 Sintef Tto As Drug delivery system for treatment of cancer

Also Published As

Publication number Publication date
EP3946253A1 (en) 2022-02-09
CN111989087A (zh) 2020-11-24
CA3134923A1 (en) 2020-10-01
JP7317038B2 (ja) 2023-07-28
US11806330B2 (en) 2023-11-07
BR112020019452A2 (pt) 2021-01-05
WO2019185685A1 (en) 2019-10-03
AU2019437385A1 (en) 2021-11-04
JP2021519323A (ja) 2021-08-10
US20200061019A1 (en) 2020-02-27
CN113840594A (zh) 2021-12-24
US20190298682A1 (en) 2019-10-03
JP2022527858A (ja) 2022-06-06
US20210113482A1 (en) 2021-04-22
EP3773471A1 (en) 2021-02-17
WO2020192950A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
BR112021019003A2 (pt) Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CL2017003458A1 (es) Metodos para tratar malignidad hematoligica usando terapia de combinacion del inhibidor de nanoparticulas mtor.
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
CL2017003457A1 (es) Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor.
BR112018010418A8 (pt) complexo de agente quimioterápico em microbolhas para terapia sonodinâmica
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
NZ745556A (en) Androgen receptor modulator and uses thereof
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
ECSP11011552A (es) Administracion continua de cilengitida en tratamientos contra el cancer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
PH12018501451A1 (en) Formulations for treating bladder cancer
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
BR112017009845A2 (pt) dianidrogalactitol juntamente com radiação para tratar carcinoma de célula não pequena dos pulmões e glioblastoma multiforme
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
ZA201908446B (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
BR112018011203A2 (pt) terapia de combinação para câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]